Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTA: Vicinium in BCG-Unresponsive NMIBC
NCT02449239Phase 3Completed
- Sponsor
- Sesen Bio
- Start
- Aug 2015
- Primary completion
- May 2020
- Modality
- scFv Fragments, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 2
01
Overview
A Phase 3 trial of oportuzumab monatox in non-muscle-invasive bladder cancer (NMIBC), sponsored by Sesen Bio. Started Aug 2015; status: completed.
02
Drugs
oportuzumab monatox
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02449239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02449239.